Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Preferred Shares: 2009-2017

  • Northwest Biotherapeutics' Preferred Shares was N/A to $12.6 million in Q4 2017 from the same period last year, while for Dec 2017 it was $12.6 million, marking a year-over-year change of. This contributed to the annual value of $12.6 million for FY2017, which is N/A change from last year.
  • As of Q4 2017, Northwest Biotherapeutics' Preferred Shares stood at $12.6 million, which was up 712.44% from $1.6 million recorded in Q2 2013.
  • In the past 5 years, Northwest Biotherapeutics' Preferred Shares registered a high of $12.6 million during Q4 2017, and its lowest value of $1.6 million during Q2 2013.
  • Moreover, its 1-year median value for Preferred Shares was $12.6 million (2017), whereas its average is $12.6 million.